Dear Doctors: Lately, we’ve been seeing a lot of ads on TV for a medication to treat thyroid eye disease. My daughter, who is 23, suffers from dry eyes, and now she’s sure she has it. What is thyroid ...

—Even long after the active phase of thyroid eye disease has subsided, a multitude of challenging quality-of-life issues may persist. Several recent studies have established that the physical ...

The most useful biomarker for extraocular muscle enlargement in thyroid eye disease (TED) is unclear. According to this study, higher thyroid-stimulating antibody (TSAb) levels and older age were ...

As mentioned in Overview, most thyroid eye disease (TED) cases are closely related to hyperthyroidism. Approximately 85% of patients with TED develop the disease around 18 months before or after the ...

However, with scarce training, few region-specific guidelines, and symptoms that often mimic common eye problems, many ...

Q: Lately, we've been seeing a lot of ads on TV for a medication to treat thyroid eye disease. My daughter, who is 23, suffers from dry eyes, and now she's sure she has it. What is thyroid eye disease ...

Decompression and teprotumumab are effective for treating pediatric patients with thyroid eye disease (TED), according to a ...

A new consensus statement from the American Thyroid Association (ATA) and European Thyroid Association (ETA) offers recommendations for endocrinologists on the management of thyroid eye disease (TED), ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. “COVID-19 vaccines are associated with a 3.2-fold ...

Artificial intelligence (AI) can help diagnose thyroid eye disease and assess its severity by analyzing CT scans, research shows. The technology could automate screening and help ensure patients who ...

BOSTON—Most patients with thyroid eye disease treated with teprotumumab didn’t require additional treatments nearly 2 years later, according to industry-supported research being presented Sunday at ...

William Blair starts coverage of Viridian, citing veligrotug's advantages over Tepezza and key 2026 catalysts, including FDA ...